First human test of new cancer drug halted
NCT ID NCT05229601
Summary
This early-stage study aimed to find a safe dose of a new drug called HFB301001 for adults with advanced cancers that had stopped responding to standard treatments. It involved 31 patients with cancers like sarcoma, kidney, liver, and melanoma. The trial was designed to test increasing doses to check safety and has since been terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NEXT Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.